Company / Cash & Equivalents
MANNKIND CORP Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$74.9M
FY2025
5-year range
$46.3M / $238.5M
FY2021-FY2025
Trend
+61.6%
vs FY2024
Sector context
#165 of 209
Health Care
What the data says
MANNKIND CORP's cash & equivalents of $75M is lower than 79% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 10 years, ranging from $23M in FY2016 to $238M in FY2023.
Based on SEC 10-K filings.
$75M in FY2025 with a 5-year CAGR of +2.2%.
Declined from $238M to $75M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +2.4%
- 5-Year CAGR
- +2.2%
- 10-Year CAGR
- -
Sector benchmark
Bottom 21% in Health CareTop 79% of 209This company $74.9M Sector average $696.0M
▼
-89.2% below sector average
Key checks
Key Insights
- 5-year CAGR of +2.2%, indicating consistent growth.
- In FY2025, cash & equivalents increased 61.6% year-over-year.
- Ranks #165 out of 209 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -2.74 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $74.9M | +61.6% |
| FY2024 | $46.3M | -80.6% |
| FY2023 | $238.5M | +241.8% |
| FY2022 | $69.8M | -43.8% |
| FY2021 | $124.2M | +85.3% |
| FY2020 | $67.0M | +124.1% |
| FY2019 | $29.9M | -58.0% |
| FY2018 | $71.2M | +61.9% |
| FY2017 | $43.9M | +91.9% |
| FY2016 | $22.9M | -61.2% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026